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Introduction
The ability of  tissues to grow to their proper size during development and sustain cell renewal after tissue 
damage is critical to the maintenance of  organ function throughout life. Innate immune cells of  myeloid 
lineages are key to these processes. Thus, growth of  virtually all organs is severely impaired in animal 
models deficient in myeloid cells (1, 2), and global depletion of  myeloid cells in adulthood blunts tissue 
regeneration following injury (3–8). Loss of  myeloid cell–driven tissue remodeling and growth factor sig-
nals has been implicated in these defects (9, 10). Yet, to date, knowledge regarding the specific myeloid 
populations contributing to growth effects in different tissue contexts is limited. In fact, there is substantial 
heterogeneity in myeloid subsets present in different anatomic locations, their trafficking pattern, and the 
repertoires of  functional specialization that they can adopt in various organs (11–14). Thus, it remains 
unknown whether select myeloid populations are associated with stage-specific tissue growth versus quies-
cence and/or are required for organ’s functions.
Lineage-tracing experiments have shown that myeloid cell heterogeneity in different organs is contrib-
uted by the presence of  ontogenically distinct subsets. One of  these populations originates from the yolk 
sack (YS), the site of  “primitive hemopoiesis,” whereas other subsets may derive from hemopoietic stem 
cells (HSCs) originating in fetal liver or bone marrow (BM), sites of  “definitive hemopoiesis” (15, 16). 
These subsets give rise to phenotypically distinct macrophage populations, the YS-derived one defined as 
CD11b+LY6CloF480+CX3CR1+CCR2– or “resident” and the HSC-derived subset exhibiting a CD11b+LY-
6ChiF480+CX3CR1–CCR2+ phenotype. Interestingly, there is evidence that these two populations differ in 
their persistence and capacity to self-renew locally, ultimately leading to a relative contribution of  the two 
subsets that is profoundly different from one organ to another. For example, YS-derived CX3CR1+ myeloid 
cells account for most brain microglia as well as lung and skin macrophages and are relatively long lived 
(15, 17–19). In contrast, HSC-derived CCR2+ cells predominate and constantly turn over in tissues under-
going cyclic cell renewal, such as the intestine, uterus, and mammary gland (20–23), and may be transiently 
Organ-specific patterns of myeloid cells may contribute tissue-specific growth and/or regenerative 
potentials. The perinatal stage of pancreas development marks a time characterized by maximal 
proliferation of pancreatic islets, ensuring the maintenance of glucose homeostasis throughout 
life. Ontogenically distinct CX3CR1+ and CCR2+ macrophage populations have been reported in the 
adult pancreas, but their functional contribution to islet cell growth at birth remains unknown. 
Here, we uncovered a temporally restricted requirement for CCR2+ myeloid cells in the perinatal 
proliferation of the endocrine pancreatic epithelium. CCR2+ macrophages are transiently enriched 
over CX3CR1+ subsets in the neonatal pancreas through both local expansion and recruitment of 
immature precursors. Using CCR2-specific depletion models, we show that loss of this myeloid 
population leads to a striking reduction in β cell proliferation, dysfunctional islet phenotypes, and 
glucose intolerance in newborns. Replenishment of pancreatic CCR2+ myeloid compartments by 
adoptive transfer rescues these defects. Gene profiling identifies pancreatic CCR2+ myeloid cells as 
a prominent source of IGF2, which contributes to IGF1R-mediated islet proliferation. These findings 
uncover proproliferative functions of CCR2+ myeloid subsets and identify myeloid-dependent 
regulation of IGF signaling as a local cue supporting pancreatic proliferation.
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recruited to injured sites (24, 25). In some organs, there is also evidence that the balance between these two 
subsets changes with age (4, 20), paralleled by changes in tissue repair (26, 27). These observations indicate 
that distinct myeloid populations populate different organs following tissue-specific and developmentally 
regulated dynamics and may contribute to organ- and/or age-specific growth and regenerative potentials.
Postnatal proliferation is limited in pancreatic islet β cells, the endocrine component of  the pancreas 
responsible for the maintenance of  glucose homeostasis. In mice, the islet β cell mass is established through 
processes of  islet neogenesis from undifferentiated precursors during embryogenesis, and massive cell expan-
sion is restricted to about 2 weeks after birth (28). Beyond this perinatal stage, the rate of  islet proliferation 
declines dramatically (29, 30). Inadequate β cell expansion at this stage has been proposed to underlie dia-
betic conditions associated with metabolic stress later in life. Presently, it is unknown whether the short peri-
natal time window most permissive to islet cell growth depends on the presence of  select pancreatic myeloid 
populations that control the establishment of  islet cell mass. Defects in islet cell expansion were noted in 
animal models deficient of  macrophage survival factors (31, 32), suggesting a role of  these myeloid cells in 
pancreatic cell growth. Most recently, embryonic and HSC-derived myeloid cells were reported in the adult 
pancreas (33), but their functional effect on islet growth early after birth remains unknown.
Here, we uncover distinct functional properties of  CCR2+ myeloid cells regarding their ability to 
transiently populate discrete compartments of  the pancreas and proliferate locally after birth. Using 
CCR2-specific ablation, repopulation, and cell culture models, we further demonstrate that CCR2+ cells 
are required for postnatal proliferation of  the pancreatic endocrine epithelium and contribute to positive 
regulation of  IGF signaling in this tissue.
Results
Phenotypically distinct myeloid subsets are selectively enriched in discrete compartments of  the pancreas and at distinct 
developmental stages. We compared the myeloid cellular composition of  the E14.5 pancreas, a stage character-
ized by substantial islet neogenesis, with that of  the newborn pancreas, a stage in which islet cells undergo 
a major wave of  expansion (28). Tissues were dissociated by a modified collagenase method (34) to yield 
>95% pure mesenchymal fractions and >85% and >70% enriched epithelial fractions from E14.5 and new-
born pancreata, respectively, as measured by flow cytometry for the epithelial marker EpCAM (data not 
shown). Splenocytes obtained by the same collagenase treatment served as controls of  circulating myeloid 
populations. Flow cytometric analysis for myeloid markers CD11b, F480, and GR1 demonstrated that the 
mesenchymal fraction of  the E14.5 pancreas comprises GR1+F480– granulocytes, GR1–F480+ macrophages, 
and GR1+F480+ cells (Figure 1A). The F480+GR1+ subset was substantially more abundant in the pancreatic 
mesenchyme of  newborn pancreas as compared with that of  E14.5 pancreas (i.e., 57% vs. 13% of  CD11b+ 
cells). In contrast, the epithelial compartment of  E14.5 pancreas contained a myeloid cell subset resistant to 
collagenase and exhibited a bona fide F480+GR1– macrophage phenotype (Figure 1A). Further analysis for 
expression of  CX3CR1 and CCR2 revealed that CCR2+F480+ cells preferentially segregated with pancreatic 
mesenchymal fractions and were substantially enriched in the neonatal pancreas (Figure 1, A–C, red histo-
grams; 53.2 × 103 ± 1.1 × 103 cells/pancreas at P1 vs. 1.6 × 103 ± 0.2 × 103 cells/pancreas at E14.5, mean 
± SEM, n = 3). In contrast, CCR2–CX3CR1+F480+ cells were highly enriched within the epithelial fraction 
of  E14.5 pancreas (Figure 1, A–C, blue histograms; 8.7 × 103 ± 1.2 × 103 cells/pancreas at E14.5 vs. 0.76 × 
103 ± 0.28 × 103 cells/pancreas at P1, mean ± SEM, n = 3). The distribution of  CX3CR1+ and CCR2+ pop-
ulations in the pancreas was distinct from that in the spleen, indicating a pancreatic tissue-specific pattern.
Analysis of  myeloid cells exhibiting an F480+CCR2+ phenotype in postnatal pancreatic tissue demon-
strated that their number decreases with age (Figure 1D). Concomitantly, we detected a marked, reduced 
expression of  chemotactic ligands for CCR2 (e.g., CCL2, CCL7, CCL8) in pancreatic mesenchymal 
fractions (Figure 1E), suggesting time-restricted conditions permissive to the recruitment of  CCR2+ cells 
in the pancreas. Since CCR2+ cells comprise a small subset of  myeloid precursors (35), we extended these 
studies to determine the potential contribution of  multipotent progenitors to pancreatic myeloid pools, 
as measured by CFU assays. These studies revealed a very high frequency of  myeloid CFUs in P1 and 
P5 pancreata, even exceeding that detected in the spleen (Figure 1F). Frequencies of  these progenitors, 
however, declined after birth (Figure 1F).
Analysis of  pancreatic tissue from CCR2RFP/+ reporter mice confirmed the more abundant representa-
tion of  CCR2+ cells in newborn pancreas versus E14.5 and adult pancreas (Figure 2A). CCR2+RFP+ cells 
that populated the newborn pancreas resided within the mesenchyme surrounding acinar and endocrine 
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epithelial clusters (Figure 2, B–D), just outside the basal membranes of  blood vessels (Figure 2, E and F), 
and/or adjacent to epithelial clusters (Figure 2, G and H). Most pancreatic CCR2+RFP+ cells expressed 
F480 (Figure 2H, arrowheads). Flow cytometric cell sorting, followed by Wright-Giemsa staining, demon-
strated that CD11b+CCR2+ cells isolated from P1 pancreas appear morphologically as large tissue macro-
phages, whereas splenic CCR2+ myeloid cells are monocytic-like cells (Figure 3A). Further flow cytometric 
analysis showed that, as compared with their splenic counterparts, pancreatic CCR2+ cells lack Ly6G and 
have downregulated GR1 expression, indicating that they do not comprise neutrophils and have progressed 
beyond the phenotype of  recent tissue migrants (36). In contrast, they exhibited upregulated levels of  F480, 
CD115, and the scavenger receptors CD206 and CD93, markers of  mature tissue macrophages (Figure 
3B). Dendritic cell markers (e.g., CD11c, CD1a) were absent within the CCR2+ population of  P1 pancreata 
(data not shown).
Tissue macrophages may arise from circulating monocytes or are generated through proliferation 
within the tissue (17, 19). In vivo BrdU pulsing of  CCR2RFP/+ newborn mice demonstrated that FSChi 
macrophage-like CD11b+CCR2+ and FSClo monocytoid-like CD11b+CCR2+ cells present in the neona-
tal pancreas and spleen, respectively, were highly proliferative as compared with CD11b+CCR2– frac-
tions (Figure 3C). By 2 weeks after birth, however, most pancreatic CD11b+CCR2+ cells returned to 
quiescence, whereas splenic CCR2+ subsets continued to expand (Figure 3C). Hence, pancreatic CCR2+ 
myeloid cells are distinct from those present in the peripheral circulation, exhibit morphologic and 
surface marker phenotypes typical of  tissue macrophages, and proliferate locally, though transiently, 
within the neonatal pancreas.
Figure 1. Distribution and age-associated changes of myeloid subsets in distinct pancreatic tissue compartments. (A) Flow cytometric analysis of GR1+ 
and F480+ subsets in mesenchymal and epithelial fractions of E15.5 and newborn pancreas (n = 3). (B) F480+ gates showing enrichment of CCR2+ mac-
rophages in the mesenchymal fraction of newborn pancreas, whereas CX3CR1+ subsets predominate within the epithelial fraction of E15.5 pancreas. (C) 
Contingency plots showing the number of F480+CX3CR1+ and CCR2+ subsets detected in E15.5 and newborn pancreas (mean ± SEM of 3 tissue samples). 
(D) Age-associated changes in the frequency of pancreatic F480+CCR2+ cells (mean ± SD of at least 2 tissue pools per time point). (E) qPCR of chemokine 
transcripts in mesenchymal fractions of E14.5, P1, and 4-week-old pancreas (mean ± SD of triplicates) (n = 2, using pools of 3–5 tissues per time point). (F) 
Myeloid CFU outgrowth from 100,000 cells/tissue (mean ± SD of n = 2 tissue pools, each run in duplicate cultures).
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Depletion of  CCR2+ myeloid cells severely impairs the growth of  pancreatic endocrine and exocrine epithelial com-
partments. The substantial increase in number of  CCR2+ myeloid cells found in the neonatal pancreas raised 
the question whether this myeloid subset contributes proproliferative cues to pancreatic epithelia after birth.
To investigate this question, we used a transgenic model in which the CCR2 promoter drives expres-
sion of  the diphtheria toxin (DT) receptor, allowing for selective depletion of  CCR2+ cells upon DT 
Figure 2. Localization of CCR2+ myeloid cells in the pancreas. (A) Pancreatic sections from E14.5, P1, and adult CCR2WT/RFP mice, stained for RFP to 
visualize CCR2+ cells in situ. (B–D) Pancreatic sections from P1 CCR2WT/RFP mice stained for RFP, insulin, and the epithelial marker EpCAM. (E–H) The 
same tissue sections stained for RFP, insulin, and the vascular markers CD31 (E) and collagen IV (F and G), or the epithelial marker E-cadherin and 
the macrophage marker F480 (H). CCR2–RFP+ cells occupy the interacinar and peri-islet interstitial space (B–D), outline the extraluminal side of blood 
vessels (E and F, arrowheads), or line Ep-CAM+ and E-cadherin+ epithelial clusters (G and H, arrowheads). Most CCR2+ cells coexpress F480 (H, arrow-
heads). Scale bars: 50 μm (A); 40 μm (B); 25 μm (C–F); and 20 μm (G and H). Representative of n = 10 experiments.
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injection (37). Using this mouse model, we 
achieved consistent depletion of  CD11b+C-
CR2+ myeloid cells in the BM, spleen, and 
pancreas in CCR2 DTR/+ newborns upon 4 
DT injections administered every 48 hours 
starting at P2 (Figure 4A). DT treatment 
of  CCR2 DTR/+CX3CR1GFP/+ reporter pups 
demonstrated that CCR2+ cell ablation did 
not significantly affect the frequency of  
CD11b+CX3CR1+CCR2– macrophages (Fig-
ure 4B). Moreover, in line with the predom-
inant expression of  CCR2 in CD11b+GR1+ 
cells and a subset of  immature GMP progen-
itors (35), DT injection depleted about 50% 
of  CD11b+GR1+ and Ly6G+ cells in all three 
tissue compartments, whereas it did not sig-
nificantly affect CD3+ T/NK or B220+ B cell 
populations (Figure 5). In addition, in spite 
of  the reported potential of  CCR2+ myeloid 
cells to influence angiogenesis (38), deple-
tion of  CCR2+ cells did not negatively affect 
vascular density, as measured by morpho-
metric analysis of  vascular areas identified 
by CD31 immunostaining and quantitative 
flow cytometry of  CD45–CD31+ endothelial 
cells in pancreatic collagenase digests (Sup-
plemental Figure 1; supplemental material 
available online with this article; https://
doi.org/10.1172/jci.insight.93834DS1).
To assess whether ablation of  CCR2+ myeloid subsets affected pancreatic epithelial cell growth, pan-
creata from DT-treated CCR2DTR/+ and control mice were harvested at P10 and immunostained for the 
proliferation marker PCNA as well as the exocrine and endocrine markers amylase and insulin. Mor-
phometric analysis revealed that epithelial cell proliferation was significantly decreased in DT-treated 
CCR2DTR/+ mice in both the exocrine and endocrine compartments (Figure 6, A–C). Accordingly, we 
measured 60%–70% reduction of  the exocrine and β cell areas in DT-treated CCR2DTR/+ mice, as com-
pared with controls (Figure 6, D and E). When normalized to body weight, amylase and β cell areas in 
DT-treated CCR2DTR/+ mice decreased by 47% and 26%, respectively. The frequency of  apoptotic cells in 
pancreatic tissue was low, although it was slightly increased in DT-treated CCR2DTR/+ mice (Figure 6F). 
There were not apparent differences in size distribution of  the islets areas measured in situ by histolo-
gy in CCR2DTR/+ mice versus control mice. In addition, morphometric analysis of  other islet endocrine 
cell types, i.e., glucagon+, somatostatin+, and PP+ cells, demonstrated that the architectural organization 
and relative representation of  β, α, δ, and PP cells within the islets was similar in DT-treated WT and 
Figure 3. Phenotype of CCR2+ myeloid subsets. 
(A) Morphology of CD11b+CCR2+ myeloid cells 
sorted from spleen and pancreas of P1 WT mice 
stained by Wright-Giemsa (n = 3). (B) Flow cyto-
metric analysis of pancreatic and splenic CCR2+ 
cells for myeloid cell markers. Vertical gray lines 
mark background fluorescence of IgG controls. 
Representative of n = 4 experiments. (C) Flow 
cytometric plots showing the fraction of BrdU+ 
cells detected in pancreatic and splenic CD11b+C-
CR2+ and CD11b+CCR2– subsets from P1 and P15 
newborns after a 16 hours pulse in vivo (n = 4, 
using pools of 3–4 tissue samples).
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CCR2DTR/+ pups (i.e., 58% ± 2.8% vs. 61.6% ± 3.3% β cells, 23.8% ± 2.5% vs. 20.8% ± 3.5% α cells, 2.2% 
± 0.6% vs. 3.2% ± 0.4% δ cells, 2.6% ± 0.4% vs. 2.7% ± 0.4% PP cells in DT-treated WT vs. CCR2DTR/+ 
mice, respectively, mean ± SD, n = 3).
In order to examine the consequences of  depleting CCR2+ myeloid populations in situ, independently 
of  potential systemic effects of  the ablation, we prepared pancreatic explants from P2 CCR2DTR/+ and WT 
mice and treated them with DT for 5 days in organ cultures. Morphometric analysis for the pan-epithelial 
marker E-cadherin and PCNA demonstrated that depletion of  CCR2+ cells in this culture model results 
in significantly decreased epithelial cell proliferation (Figure 6G). RT-PCR of  CCR2-specific mRNA at 
the end of  the culture showed decreased levels of  CCR2 transcripts in DT-treated CCR2DTR/+ samples 
relative to control samples, thereby validating specificity and efficiency of  depletion of  the CCR2+ sub-
set (Figure 6H). These results demonstrate that blunted proliferation of  pancreatic epithelium following 
loss of  CCR2+ cells may occur ex vivo independent of  possible systemic effects of  the depletion, thereby 
Figure 4. Quantitative analysis of leukocyte subsets in BM, splenic, and pancreatic tissue compartments of CCR2DTR/+ and WT mice treated with diphthe-
ria toxin. (A) Flow cytometric analysis of CD11b+CCR2+ subsets obtained from BM, spleen, and pancreas of P10 mice, showing depletion of CCR2+ cells in all 
tissue compartments of diphtheria toxin–treated (DT-treated) CCR2DTR/+ mice, as compared with controls. (B) Same analysis in DT-treated CCR2DTR/+CX3CR1GFP/+ 
mice and CCR2+/+CX3CR1GFP/+ controls at P10, showing persistence of CCR2–CX3CR1+ macrophages. Representative of n = 4 experiments.
Figure 5. Cumulative flow cytometric analysis of leukocyte subsets in the indicated tissue compartments. CCR2+, GR1+, and LY6G+ cells were gated within the 
CD11b+ subset. Diphtheria toxin (DT) treatment effectively depletes CD11b+CCR2+ cells and partially affects GR1+ and LY6G+ subsets but not B220+ (B cells) and CD3+ 
(T/NK) cells (mean ± SEM of n = 6–17 determinations per group). **P < 0.01, ***P < 0.001, 1-way ANOVA nonparametric test, followed by Bonferroni post-hoc test.
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supporting a functional link between the presence 
of  this myeloid subset within the pancreatic tis-
sue niche and epithelial proliferation.
Depletion of  CCR2+ myeloid cells is associated with 
decreased body weight and dysfunctional islet phenotypes. 
In addition to affecting pancreatic growth, depletion 
of CCR2+ myeloid cells had two other noticeable 
effects. First, DT-treated CCR2DTR/+ mice had sig-
nificantly lower body weight than DT-treated WT 
and untreated controls (Figure 7, A and B). They 
also exhibited a mild fasting hypoglycemia (Figure 
7C). We excluded the possibility that this hypoglyce-
mia was due to aberrant feeding behavior, since both 
hypoglycemic and nonhypoglycemic pups consis-
tently had milk in their stomach. Rather, we found 
that DT-treated CCR2DTR/+ pups had decreased 
glycogen storages in muscle and liver (Figure 7D). 
Basal serum insulin levels were lower than normal 
(Figure 7E), whereas glucagon levels were not sig-
nificantly different than those of controls (i.e., 54.7 
± 6.5 pg/ml in DT-treated CCR2DTR/+ mice vs. 48 ± 
3 pg/ml in DT-treated WT mice, mean ± SEM, n = 
5). These results suggest that impaired accumulation 
of glycogen and insulin insufficiency undermining 
glycogen synthesis may contribute to their defect in 
glucose homeostasis under basal conditions. To fur-
ther evaluate β cell function, we performed glucose 
tolerance tests on DT-treated CCR2DTR/+ mice and 
WT littermates at P10. These studies revealed that 
depletion of CCR2+ cells is associated with glucose 
intolerance in CCR2DTR/+ mice (Figure 7F).
The altered glucose homeostasis displayed by DT-treated CCR2DTR/+ mice suggested an islet immature 
phenotype. Indeed, in addition to increased cell proliferation, an important adaptive response of pancreatic 
islets to the changed metabolic conditions occurring in perinatal life involves modulation of islet transcriptional 
Figure 6. Effects of CCR2+ cell depletion on the prolif-
eration of the exocrine and endocrine compartments 
of the pancreas. (A) Pancreatic sections of diphthe-
ria toxin–treated (DT-treated) P10 mice stained for 
amylase, insulin and the proliferation marker PCNA. 
Scale bar: 50 μm. Representative of at least n = 4 per 
group. (B and C) Frequency of PCNA+ cells detected 
within amylase+ (B) and insulin+ (C) areas. (D and E) 
Morphometric analysis of amylase+ and insulin+ areas. 
(F) Frequency of TUNEL+ apoptotic cells in pancreatic 
epithelial tissue identified by E-cadherin staining. (B–F) 
Mean ± SEM of n = 3–4 mice per group. (G) Frequency 
of proliferating epithelial cells in P2 pancreatic explants 
from CCR2DTR/+ mice and WT littermates after culture 
in the presence or absence of DT (n = 2–4 experiments 
using pools of 3–4 pancreata). (H) PCR analysis of CCR2 
and CD11b mRNA transcripts in organ cultures shown in 
G, validating the depletion of CCR2+ cells in DT-treated 
CCR2DTR/+ tissues. Mean + SD. Representative of n = 2–4 
experiments. *P < 0.05, **P < 0.01, ***P < 0.001, 1-way 
ANOVA nonparametric test, followed by Bonferroni 
post-hoc test.
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Figure 7. Effects of CCR2+ cell depletion on body size and glycemic homeostatic control. (A) Decreased body size of DT-treated CCR2DTR/+ mice compared 
with WT littermates at P10. (B) Body weight of untreated or DT-treated CCR2DTR/+ mice and WT littermates at P10 (n = 27–71). (C) Mild basal hypoglycemia 
detected in DT-treated CCR2DTR/+ mice at P10 (n = 9–16). (D) Tissue sections of liver and skeletal muscle stained by periodic acid–Schiff, showing decreased 
Downloaded from http://insight.jci.org on August 3, 2017.   https://doi.org/10.1172/jci.insight.93834
9insight.jci.org   https://doi.org/10.1172/jci.insight.93834
R E S E A R C H  A R T I C L E
programs dependent on NKX6.1, MafA, and MafB, which foster functional maturation of islet cells (39–41). 
To investigate whether depletion of CCR2+ myeloid cells was associated with changes in the expression of  
these transcription factors, pancreatic sections were immunostained with NKX6.1-, MafA-, and MafB-specific 
antibodies. This analysis revealed that expression of NKX6.1 and MafA was substantially lower in DT-treated 
CCR2DTR/+ mice as compared with controls (Figure 7, G and H). We also observed increased coexpression 
of MafB in PDX1+Ins+ cells in DT-treated CCR2DTR/+ mice (Figure 7I, and Supplemental Figure 2), a phe-
notype reminiscent of islets at fetal, rather than postnatal, stages of development (40). Western blotting of  
islet protein extracts confirmed the reduced expression of NKX6.1 and MafA (Figure 7J). Analysis of other 
islet transcription factors (i.e., PDX1, PAX6a, NeuroD) by RT-PCR revealed no overt differential expression 
between DT-treated CCR2DTR/+ mice and controls; a notable exception was neurogenin 3, which was upregu-
lated in DT-treated CCR2DTR/+ islets (Figure 7K). This latter finding is consistent with the phenotype described 
in NKX6.1 gene–knockout mice and in human type 2 diabetes, a trait proposed to be associated with partial 
dedifferentiation of β cells (42, 43). Ex vivo assessment of endocrine function demonstrated that islets purified 
from DT-treated CCR2DTR/+ mice exhibited a decreased insulin content and a high basal insulin secretion 
under low glucose (i.e., 2.8 mM) culture conditions and responded poorly to high glucose concentrations (i.e., 
16.7 mM) as compared with those isolated from WT littermates (i.e., ~1.6- vs. 3.5-fold change over basal 
insulin secretion in islets from DT-treated CCR2DTR/+ mice vs. DT-treated WT littermates, Figure 7L). Hence, 
loss of CCR2+ myeloid cells in perinatal life affects not only the proliferation of the pancreatic epithelium, but 
also islet function. Specifically, it impairs the β cells’ ability to maintain NKX6.1 expression, turn on MafA 
over MafB, and acquire normal insulin secretory responses, all traits pointing to an ineffective progression of  
pancreatic islets toward functional maturity.
Adoptive transfer of  DT-resistant BM-derived GR1+CCR2+ myeloid cells reconstitutes CCR2+ tissue compartments 
and rescues pancreatic tissue growth. To gather further evidence for the requirement of  CCR2+ myeloid cells 
in pancreatic cell proliferation, we next investigated whether adoptive transfer of  DT-resistant myeloid 
cells into DT-treated CCR2DTR/+ newborns would rescue the growth defects of  the endocrine and exocrine 
compartments of  the pancreas. Figure 8A shows flow cytometry plots of  the myeloid populations used for 
adoptive transfer and the timeline of  DT and cell injections. To provide the recipient mice with a source of  
DT-resistant cells readily available for deployment into tissues while maintaining the time frame of  DT-me-
diated depletion of  the endogenous cells (i.e., P2–P10), the mice were simultaneously injected with donor 
cells and DT, each injection being staggered at 48-hour intervals. Since DT depletion affected CCR2+GR1+ 
cells as well as approximately 50% of  the total GR1+ myeloid population (Figure 5), in a first set of  exper-
iments, we transferred whole GR1+ cells isolated from adult BM to newborns. In addition, in order to 
minimize interference of  surface-bound antibodies with tissue homing, and to be able to track donor cells 
in vivo, GR1+ cells were purified by negative selection from BM of  transgenic mice ubiquitously expressing 
GFP in all cell types. Flow cytometric analysis for the pan-leukocyte marker CD45 and the myeloid marker 
CD11b indicated that the resulting purified population was 99% CD45+GR1+ (Figure 8A). Alternatively, 
to selectively track donor CCR2+ cells in vivo and to specifically assess the rescue by this subset in recipient 
mice, CCR2+ cells were purified from BM-derived GR1+ cells of  CCR2RFP/+ reporter mice by sorting.
In titration experiments, flow cytometric analysis of  CD11b+CCR2+GFP+ cells in BM, spleen, and 
pancreatic tissues at P10 revealed that 3 injections of  2 × 106 to 3 × 106 GR1+ cells/mouse replenished 
the pancreatic CCR2+ compartment of  DT-treated CCR2DTR/+ mice up to approximately 70% of  that 
measured in WT controls (Figure 8B). Cell-injected CCR2DTR/+ mice also displayed improved body 
weight (i.e., 4.3 ± 0.3 g vs. 3.1 ± 0.9 g in nonrescued mice, Figure 7B and Figure 8C) and had a normal 
basal glycemia (Figure 8C).
glycogen storages in DT-treated CCR2DTR/+ P10 pups. Scale bar: 50 μm. Representative of n = 4. (E and F) Basal plasma insulin (E) (n = 4–5) and glucose 
tolerance tests (F) (n = 7–9) in P10 DT-treated CCR2DTR/+ mice and WT littermates. **P < 0.01, ***P < 0.001, 1-way ANOVA nonparametric test, followed 
by Bonferroni post-hoc test. (G–I) Pancreatic sections from P10 DT-treated WT and CCR2DTR/+ mice stained for the islet markers NCAM and NKX6.1 (G); 
islet transcription factor MafA and E-cadherin (H); and islet transcription factors PDX1 and MafB (I). Insets in G and H show NKX6.1 and MafA localization 
to the islets’ nuclei, whereas insets in I show aberrant persistence of MafB in PDX+ cells in DT-treated CCR2DTR/+ mice (arrowheads). Representative of at 
least n = 6 per group. (J) Western blotting of NKX6.1 and MafA expressed in total protein lysates of P10 pancreatic islets. Membranes were stripped and 
reprobed for E-cadherin and Hsp90 as loading controls (n = 3). (K) Representative qPCR analysis of islet transcription factors mRNAs in pancreatic islets 
of DT-treated WT and CCR2DTR/+ mice at P10 (n = 2) (mean ± SD of triplicates). (L) Insulin content and glucose-stimulated insulin secretion of islets isolated 
from DT-treated WT and CCR2DTR/+ mice at P10 (n = 3–4). *P < 0.05, ***P < 0.001 by 2-tailed Student’s t test used for insulin content and by 1-way ANOVA 
nonparametric test for multiple comparisons of insulin secretion.
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Interestingly, gating on GFP+ cells demonstrated that contribution of  donor cells to CD11b+C-
CR2+ subsets was most prevalent in pancreatic tissue as compared with BM and splenic compartments 
(Figure 8D), suggesting preferential homing and/or survival of  CCR2+ cells in this organ. In addition, 
within the pancreas, the contribution of  GFP+ donor cells was consistently more robust in CCR2DTR/+ 
mice than in WT controls, indicating that depletion of  endogenous myeloid cells facilitated repopu-
lation of  the macrophage pools of  this organ. Immunostaining of  pancreatic sections for epithelial 
markers (i.e., E-cadherin or EpCAM), insulin, and donor-derived GFP or RFP demonstrated that 
myeloid cells of  donor origin repopulated both the exocrine and endocrine compartments, in many 
instances localizing right within islet structures (Figure 9A). Importantly, morphometric analysis of  
proliferating PCNA+insulin+ and PCNA+amylase+ cells demonstrated that injection of  either GR1+ or 
sorted CCR2–RFP+ cells restored normal levels of  islet and exocrine cell proliferation (Figure 9, B–D), 
indicating that the latter population alone was sufficient to mediate the rescue effect. In addition, 
Figure 8. Adoptive transfer of DT-resistant CCR2+ cells reconstitutes the pancreatic CCR2+ myeloid pool. (A) FACS analysis of myeloid populations used 
for adoptive transfer, and time line of cell and DT injections. Adoptively transferred populations were GR1+ CD3–B220–CD11c–Ter119– cells isolated from BM 
of C57BL/6-Tg(CAG-EGFP)10sb/J or CCR2WT/RFP reporter mice, purified to >97% by negative selection, or CCR2-RFP+ cells FACS sorted from GR1+ cells based 
on RFP expression in the depicted gate. (B) Contingency plots showing the relative representation of host- and donor-derived CD11b+CCR2+ myeloid cells 
in BM, spleen, and pancreas after reconstitution of DT-treated WT and CCR2DTR/+ mice with DT-resistant GR1+GFP+ cells (mean ± SEM of n = 3–6 tissue 
samples per group and tissue type). (C) Body weight and basal glycemia in P10 WT and CCR2DTR/+ mice treated with DT and simultaneously rescued with 
DT-resistant GR1+GFP+ cells. *P < 0.05, unpaired t test. (D) Flow cytometry plots of BM and splenic and pancreatic CD11b+ myeloid cells from DT-treated 
CCR2DTR/+ WT mice (P10) reconstituted with DT-resistant GR1+GFP+ cells. Gating on GFP+ cells (bottom row) demonstrates a substantial fraction of CCR2+ 
cells of donor origin in the pancreas. Representative of n = 3 experiments.
Downloaded from http://insight.jci.org on August 3, 2017.   https://doi.org/10.1172/jci.insight.93834
1 1insight.jci.org   https://doi.org/10.1172/jci.insight.93834
R E S E A R C H  A R T I C L E
pancreatic islets of  CCR2DTR/+ mice subjected to cell transfer exhibited an expression pattern of  
NKX6.1 and MafA comparable to controls (Supplemental Figure 3).
Follow-up studies through 4 weeks of  age demonstrated that CCR2DTR/+ mice “rescued” with GR1+ 
cells had increased body weight to levels comparable to those of  untreated WT or CCR2DTR/+ controls 
(Figure 9E). Pancreas weights in rescued CCR2DTR/+ mice were also restored to normal range (Figure 
9F). In contrast, nonrescued CCR2DTR/+ mice still exhibited a lower body and pancreas weight as com-
pared with WT controls (Figure 9F). This indicates that growth defects induced by loss of  CCR2+ cells in 
perinatal stages can only be partially recovered later in life. Nevertheless, in nonrescued CCR2DTR/+ mice, 
there was evidence of  catch-up growth. For example, morphometric analysis of  the pancreas showed that, 
by 4 weeks of  age, these mice had increased β cell areas by 3.2-fold over that measured in DT-treated 
CCR2DTR/+ mice at P10 (i.e., from 0.36 ± 0.03 mm2 at P10 to 1.28 ± 0.2 mm2 at 4 weeks, mean ± SD, 
n = 3–4), whereas, during the same time span, β cell area increased in WT littermates by about 2-fold 
(i.e., from 0.8 ± 0.06 mm2 at P10 to 1.55 ± 0.4 mm2 at 4 weeks, mean ± SD, n = 3–4). Interestingly, 
Figure 9. Reconstitution of CCR2+ 
myeloid pools by DT-resistant CCR2+ 
cells rescues pancreatic epithelial pro-
liferation. (A) Pancreatic sections from 
DT-treated mice reconstituted with 
GFP+GR1+ cells, stained for E-cadherin 
or EpCAM (red), insulin (blue), and GFP 
(green). GFP+ cells populate epithe-
lial exocrine and endocrine clusters. 
Pancreatic sections from DT-treated 
CCR2DTR/+ mice reconstituted with  
CCR2+ cells from CCR2WT/RFP  
mice showing CCR2-RFP+ cells (red) 
throughout the pancreas, including islet 
structures, identified by EpCAM (green) 
and insulin (blue) immunoreactivity, 
respectively. Representative of n = 6 
experiments. (B) Pancreatic sections of 
P10 DT-treated mice rescued with GR1+ 
cells or sorted CCR2-RFP+ cells, stained 
for PCNA (red), amylase (green), and 
insulin (blue). Representative of n = 3 
experiments. Scale bars: 50 μm (A); 100 
μm (B). (C and D) Morphometric analy-
sis of proliferating PCNA+ cells detected 
within amylase+ (C) and insulin+ (D) 
areas (mean ± SEM of 3–5 mice per 
group). *P < 0.05, ***P < 0.001, 1-way 
ANOVA nonparametric test, followed 
by Bonferroni post-hoc test. (E and F) 
Body and pancreatic weights of rescued 
and not rescued CCR2DTR/+ mice and 
controls, followed up to 4 weeks of age 
(mean ± SEM of 2–3 mice per group; 
dashed lines represent average body 
and pancreas weights of untreated 
age-matched WT controls). (G) Glucose 
tolerance tests of the mice in E and 
F after 16 hours of fasting, showing 
normal glucose tolerance.
Downloaded from http://insight.jci.org on August 3, 2017.   https://doi.org/10.1172/jci.insight.93834
1 2insight.jci.org   https://doi.org/10.1172/jci.insight.93834
R E S E A R C H  A R T I C L E
flow cytometric analysis of  myeloid populations in nonrescued CCR2DTR/+ mice at intermediate stages of  
recovery, i.e., 6 days after cessation of  DT treatment, revealed an increased number of  both splenic and 
pancreatic F480+CCR2+ myeloid cells as compared with that detected in WT littermates (Supplemen-
tal Figure 4D), indicating that catch-up growth attempts in these mice were paralleled by a rebound of  
CCR2+ myeloid cells soon after DT withdrawal. In all mouse groups, assessment of  pancreatic endocrine 
Figure 10. Transcriptional profiling of CCR2+ myeloid subsets. (A) Heatmaps of select genes differentially expressed in CD11b+CCR2+ myeloid cells sorted 
from P0 and E14.5 pancreas as compared with those sorted from P0 spleen, as reference. Scales on top of each gene cluster show the range of changes 
(bright red = highest; black = lowest). (B) Validation of differentially expressed IGF-related transcripts by RT-PCR. (C) RT-PCR of IGF2 mRNA detected 
in sorted CCR2+ myeloid cells isolated from P0 spleen and pancreas (red bars) versus that measured in whole mesenchymal and epithelial fractions of 
E14.5 and P0 pancreas or CD45–CD31–EpCAM+ cells sorted from P10 islets (mean ± SEM of triplicate samples normalized to 18S). Representative of n = 2. 
(D) IGF2 immunoreactivity in pancreatic sections of P10 CCR2RFP/WT mice highlights CCR2+RFP+ cells (arrowheads). Scale bars: 30 μm (top row) and 20 μm 
(bottom row). Representative of n = 3 experiments.
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function at 4 weeks of  age by glucose tolerance tests showed a normalized response to glucose challenge 
(Figure 9G). Taken together, these findings support the conclusion that growth of  pancreatic epithelia and 
islet function in perinatal life depend upon the presence of  GR1+CCR2+ myeloid cells in the pancreatic 
microenvironment as well as upon the recruitment of  available circulating precursors.
Neonatal CCR2+ myeloid cells exhibit a prorepair gene signature and are a prominent source of  IGF2 signaling in the 
pancreas. To identify molecular pathways that may explain the progrowth and regenerative functions of  pan-
creatic CCR2+ myeloid cells, we performed whole genome transcriptional profiling of  WT CD11b+CCR2+ 
myeloid cells sorted from P0 pancreas, P0 spleens, and E14.5 pancreas. By comparing the transcriptional 
signature of  CCR2+ cells from P0 pancreas to that of  splenic CCR2+ cells from the same donor pools, we 
Figure 11. CCR2+ myeloid cells positively modulate IGF signaling in the pancreas. (A) Pancreatic sections of DT-treated WT and CCR2DTR/+ P10 mice 
stained for PDX1, pospho-IGF1Rβ, and E-cadherin or control IgGs. Note the diminished pospho-IGF1R-specific immunoreactivity in CCR2-depleted pan-
creas. (B) Western blot analysis of phosphorylated and total IGF1Rβ in whole pancreatic cell lysates from DT-treated WT and CCR2DTR/WT P10 mice. Rep-
resentative of n = 3 experiments. (C and D) Immunostaining and morphometric analysis of proliferating PCNA+ β cells in the indicated islets/myeloid 
cells cocultures. CCR2+ and CCR2– myeloid cells used in these cultures were obtained by cell sorting from P1 pancreas (mean ± SEM of 5 microscopic 
fields, n = 2). **P < 0.01, ANOVA followed by Kruskal-Wallis post-hoc test. Scale bars: 20 μm.
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aimed to identify gene sets specifically expressed in myeloid cells that seeded the pancreatic tissue at birth. On 
the other hand, by comparing the CCR2+ myeloid subsets present in P0 and E14.5 pancreata, we expected to 
identify gene sets differentially regulated within the pancreatic microenvironment, as a function of  neonatal 
versus fetal developmental stages.
We identified 452 transcripts that were significantly (i.e., P < 0.05) differentially expressed between 
pancreatic and splenic CCR2+ subsets at P0 (i.e., specific to the pancreatic myeloid subset) and 1,455 tran-
scripts that were differentially expressed in CCR2+ subsets present in P0 versus E14.5 pancreas (i.e., devel-
opmentally regulated). These two pools overlapped in 163 genes. Among these, we identified 5 groups of  
genes that clustered according to core signatures of  cell growth, macrophage functions, inflammation, cell 
migration, and ECM remodeling (Figure 10A). The first group comprised genes associated with epithe-
lial cell proliferation. This included pancreatic cell mitogens (e.g., Reg1, Fstl1, Ctgf) (34, 44, 45) and IGF2 
and genes involved in the transcriptional and posttranslational regulation of  IGFs (e.g., H19, Dlk1, Dcn, 
Igfbp5, Igfbp4, Igfbp7, Klk1, Gpc3, Ogn, Grb10, Htra1). In the second group, i.e., genes associated with macro-
phage function, pancreatic neonatal CCR2+ cells exhibited upregulation of  select markers of  M2 polariza-
tion (e.g., Mrc1, Lyve1, Nrp1, Apoe, Edg5) and phagocytosis (e.g.Scarf2, Scara3, C1qa/c, Spon2, Gp38, Msr2, 
Cd163), whereas genes associated with M1 polarization (i.e., Fpr2, Glipr1r) were downregulated.
In the third group, containing genes regulating inflammation, pancreatic neonatal CCR2+ cells showed 
high expression levels of  genes involved in the downregulation of  inflammatory responses (e.g., Gas6, 
Sepp1, Rgs16, Trem2, Socs3) and suppression of  the NF-κB pathway (e.g., Crip2, Pdlim4, Nfatc4, Olfml3), 
whereas proinflammatory genes, such as Ltb4r1, S100a8/9, Cts1, and DAP10 and genes involved in dendritic 
cell development (e.g., CSF2R) were downregulated as compared with their splenic counterparts. Within 
the cell-migration-related gene cluster, P0 pancreatic CCR2+ cells exhibited high levels of  expression of  
genes regulating transendothelial migration and chemotactic factors specific for monocytes and granulo-
cytes (e.g., CXCl1, Ccl7, Ccl11, Cxcl10), a finding consistent with a possible role of  CCR2+ macrophages in 
maintaining a large pancreatic myeloid cell pool at birth through recruitment of  circulating myeloid cells. 
Finally, a major gene cluster that showed upregulation in the P0 pancreatic subset included genes involved 
in collagen biosynthesis and fibril stabilization (e.g., Seripnh1, Bgn, Dcn, Eln, Lum, Mfap2), assembly of  
basal membranes (e.g., Dag1, Prelp, Agr), and ECM degradation (e.g., Hyal2, Ctsk, Mmp2, Mmp14, Timp2), 
indicating enhanced tissue remodeling properties, as compared with splenic and fetal subsets.
The high expression of  IGF2 in pancreatic neonatal CCR2+ myeloid cells led us to hypothesize a role 
of  this growth factor in islet cell proliferation. RT-qPCR on sorted CCR2+ pancreatic and splenic sub-
sets validated the differential expression of  IGF2 and select binding proteins transcripts detected by gene 
screening (Figure 10B). Notably, pancreatic CCR2+ myeloid cells expressed IGF2 at strikingly higher levels 
than whole pancreatic mesenchymal fractions or sorted islet cells, as detected by both mRNA analysis (Fig-
ure 10C) and in situ immunostaining (Figure 10D).
IGF2 signals cell growth primarily through IGF1 receptor (IGF1R) (46). To investigate the functional 
role of  this pathway and its dependence on myeloid cell–derived IGF, pancreatic tissue from DT-treated 
CCR2DTR/+ and WT P10 pups was analyzed for changes in phosphorylated IGF1R. In situ immunostain-
ing and Western blotting of  pancreatic cell lysates revealed a dramatic downregulation of  phosphorylated 
IGF1R in CCR2-depleted mice (Figure 11, A and B). To provide further evidence in support of  a role of  
myeloid cell–derived IGF2 in signaling islet cell growth, CD11b+CCR2+ and CD11b+CCR2neg myeloid 
cells were sorted from neonatal pancreata and cocultured with purified pancreatic islets in the presence or 
absence of  anti-IGF2 blocking antibody. Morphometric analysis of  these cultures after 24 hours revealed 
that addition of  CCR2+ but not CCR2neg cells resulted in a significant increase in the frequency of  prolifer-
ating β cells, which was reduced by IGF2-neutralizing antibodies (Figure 11, C and D).
Taken together, these results uncover the activation of  tissue-specific proregenerative gene programs in 
neonatal pancreatic CCR2+ myeloid cells. They further identify CCR2+ myeloid cells as a prominent source 
of  IGF2 in the pancreatic microenvironment and provide evidence that the CCR2+ myeloid cell pool con-
tributes to signaling though the IGF1R/IGF axis to support β cell proliferation.
Discussion
The ability of  the endocrine compartment of  the pancreas to expand and its potential to regenerate follow-
ing injury rapidly declines with age (47). Here, we show that this decline in regenerative potential occurs in 
concert with rapid changes in CCR2+ and CX3CR1+ myeloid cell pools in the pancreas. We demonstrate 
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that these myeloid populations reside in select compartments of  the pancreas, and that their expansion is 
modulated during ontogeny to create tissue niches transiently enriched for CCR2+ cells in perinatal life. 
Importantly, we demonstrate that the CCR2+ myeloid component is critical to both the growth and matu-
ration of  pancreatic islets, as depletion of  this subset leads to reduced β cell proliferation, decreased β cell 
mass, and inability to maintain glucose homeostasis. While loss of  CCR2+ cells clearly affects the growth 
of  other tissues in the body as well, organ culture experiments demonstrate that epithelial proliferation 
depends on the presence of  this myeloid subset within the pancreatic environment, and it is not merely a 
result of  an indirect systemic effect. This conclusion is further supported by the in vivo cell replacement 
studies, showing that proliferation promptly resumes upon recruitment of  circulating CCR2+ cells to the 
pancreas, even in face of  partial recovery of  body size.
The altered metabolic control following loss of  CCR2+ cells is likely contributed by both impaired 
peripheral mechanisms of  glucose disposal and by an abnormal islet phenotype characterized by decreased 
expression of  the β cell–specific transcription factors NKX6.1 and MafA. Interestingly, the hypoprolifera-
tive β cell phenotype and glucose intolerance uncovered here closely recapitulate those reported in animal 
models of  NKX6.1 and MafA haploinsufficiency (41, 48). Notably, NKX6.1 and MafA regulate postnatal 
β cell proliferation by modulating the levels of  cyclins and are required for activation of  multiple pathways 
regulating insulin production and secretion (41, 48), all functions consistent with the observed defects in β 
cell growth and maturation. An aspect emerging from our findings is the remarkable plasticity of  these two 
transcriptional phenotypes in perinatal life and their potential regulation by extracellular cues dependent 
on CCR2+ myeloid subsets. In light of  these results, it will be important to investigate whether defects of  
NKX6.1 and MafA expression reported in type 2 diabetes (49) are linked to depletion or dysfunction of  
the myeloid cell subsets identified here, either early after birth or later in life under increased metabolic 
demand. Consistent with this possibility, it was reported that ablation of  GR1+ myeloid subsets exacerbates 
glucose intolerance in animal models of  insulin resistance (50). Thus, GR1+CCR2+ myeloid subsets may be 
required for both the establishment of  a functional β cell mass at birth as well as for adaptive β cell expan-
sion and function in response to metabolic stressors throughout life.
In the CCR2DTR/+ model, DT administration primarily depleted the F480+CCR2+ subset of  tissue 
macrophages but also affected a subset of  GR1+ and Ly6G+ granulocytes in all tissue compartments. 
While bystander death of  granulocytes phagocytosing apoptotic macrophages targeted by DT (51) can-
not be excluded in this effect, this result is more likely explained by the fact that CCR2 is transcribed in 
about 30% of  early myeloid progenitors (35), making them susceptible to DT treatment. CCR2+ myeloid 
progenitors may represent precursors readily mobilized from the BM to enhance extramedullary myelo-
poiesis in the periphery (52). Accordingly, we found that cultures of  neonatal pancreas generated a high 
number of  granulocyte/macrophage colonies as compared with adult tissues, indicating that immature 
myeloid precursors may contribute to pancreatic myeloid cell pools early in life. The presence of  these 
immature progenitors combined with the high proliferative activity of  CCR2+ cells may allow for effective 
self-renewal of  pancreatic myeloid populations in situ, pointing to multiple mechanisms by which a large 
myeloid pool may be maintained in the neonatal stage independent of  remnant embryonic macrophages 
or new monocyte input from the circulation.
There is evidence that, under increased metabolic demand or after significant β cell loss, pancreatic 
cells may reactivate regenerative programs, leading to some recovery of  the islet cell mass through prolif-
eration of  remnant β cells or transdifferentiation of  other pancreatic cell types (28). These compensatory 
regenerative responses are thought to be critical to prevent β cell failure and type 2 diabetes and may 
underlie the transient recovery of  islet function observed in early-onset type 1 diabetes after immunomod-
ulatory therapies (53). Proregenerative functions of  inflammatory-like macrophages on muscle, liver, and 
neuronal cell types have been reported (24, 54, 55), and a role for macrophages in pancreatic regenerative 
programs is emerging (56, 57), although the myeloid subsets and molecular mechanisms involved remain 
unidentified. Our results demonstrate that proliferation of  pancreatic epithelia requires the presence of  
CCR2+ myeloid cells during physiological perinatal growth. Pancreatic proliferative defects following 
depletion of  CCR2+ cells appear not to be compensated for by embryonic tissue–resident macrophages 
still present in the neonatal pancreas, providing evidence for distinct functional specializations of  these 
myeloid populations (19, 20). Our gene profiling and functional studies of  pancreatic CCR2+ cells further 
identify this myeloid subset as a prominent source of  IGF2 contributing to IGF1R-mediated mitogenic 
signaling in vivo and in vitro. While consistent with β cell proproliferative effects noted in IGF2-transgenic 
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models (58, 59), these findings uncover a paracrine component of  the activation of  this signaling pathway, 
which is dependent on CCR2+ myeloid cells trafficking through the pancreas. The negative impact that 
impairing this pathway has on endocrine cell mass was previously undetected in IGF1R-knockout models, 
as the analysis focused on adult mice beyond the perinatal stage of  β cell expansion, although endocrine 
dysfunction was noted (60–62). Thus, myeloid cell–derived IGF signaling may act as a mitogen and be 
most critically needed early after birth, at the peak of  tissue growth, whereas it may be compensated for 
by other adaptive signals later in life. In addition, other cellular sources of  IGF2, e.g., autocrine β cell–
derived IGF2, were reportedly involved in regulating β cell adaptation to increased metabolic demand in 
adulthood (63). Whether epithelial- and myeloid-derived IGF2 enable distinct cell-context-specific mech-
anisms of  cell proliferation remains to be determined. Finally, it is noteworthy that CCR2+ cells isolated 
from the pancreas exhibit increased production of  other cell mitogens, e.g., follistatin-like proteins (34, 44) 
(i.e., FSTL1) and CTGF (45, 64) (Figure 10A) among others. It is possible that these factors contribute as 
well to the growth-promoting effect of  CCR2+ cells in vivo.
Adoptive transfer experiments demonstrate that CCR2+ myeloid cells isolated from adult BM share 
similar functionalities with neonatal CCR2+ myeloid subsets, for example, their ability to home to the 
pancreas, develop into F480+ macrophages, and support endocrine and exocrine cell growth. In fact, this 
subset is sufficient to rescue pancreatic growth to near physiologic levels, even beyond that supported by 
endogenous CCR2+ populations that spontaneously recover from DT withdrawal. This observation sug-
gests that mobilization of  endogenous CCR2+ cells to the pancreas and/or retention of  this subset within 
this organ are limiting under physiologic conditions. Notably, our data demonstrate levels of  reconstitution 
of  pancreatic myeloid populations by donor cells significantly higher than previously reported in adult pan-
creas by similar nonmyeloablative BM transfers (19). This suggests that the neonatal pancreas is far more 
receptive to the turnover of  CCR2+ myeloid cells than the adult one. Hence, cell replacement approaches 
using BM-derived CCR2+ subsets may be a promising strategy to boost pancreatic and islet regenerative 
programs in young hosts, particularly in settings of  myeloid cell deficiency. Since myeloid subsets function-
ally equivalent to CCR2+ murine subsets are present in humans (1), this might be directly relevant to the 
treatment of  pancreatic developmental defects associated with inherited BM failure syndromes in humans 
(65) and animal models (66).
Taken together, these studies identify functions of  CCR2+ myeloid cells that extend beyond the role of  
classical phagocytes and immune mediators to the regulation of  pancreatic cell growth and functional mat-
uration in perinatal life. They demonstrate a dynamic contribution of  CCR2+ cells to the pancreatic micro-
environment, including the ability to serve as a vehicle for bioactive IGF2, and pancreatic-specific patterns 
of  self-renewal and trafficking that differ significantly from other organs, such as the brain or the neonatal 
heart, in which resident macrophages predominate and recruitment of  CCR2+ cells is either excluded or 
observed at much later stages (18, 20). These findings suggest that, by enhancing recruitment and/or local 
expansion of  this specific myeloid subset, it may be possible to foster pancreatic islet regeneration and gain 
more effective control of  glucose homeostasis in diabetes.
Methods
Mouse breeding and treatments. WT C57BL/6J or C57BL/6J/SV129, CCR2RFP/RFP(B6.129-Cg-CCR2tm2.1/fc/J), 
CX3CR1GFP/GFP, and C57BL/6-Tg(CAG-EGFP)10sb/J mice were obtained from The Jackson Labora-
tory. The generation of  CCR2 promoter-driven DTR mice is described in Hohl et al. (37). Genotyping 
of  the CCR2DTR/+ mice was confirmed on tail lysates using the primers CATCCACGGAGAATGCAAA 
(forward) and ACCACAGCCAGGATAGTTGTATG (reverse) and the following PCR amplification 
conditions: 94°C for 5 minutes, followed by 35 cycles of  94°C for 45 seconds, 58°C for 45 seconds, and 
a 1-minute extension at 72°C. All mice were bred and housed at the University of  Washington patho-
gen-free facility. In vivo BrdU incorporation experiments were performed by a single i.p. injection of  
BrdU (100 μg/g of  body weight), followed by a 16-hour chase. DT (List Biological Laboratories Inc.) 
was injected i.p. at 10 ng/g of  body weight every 48 hours for a total of  4 injections. Diabetes was 
induced by i.p. injection of  a single dose of  streptozotocin (160 mg/g body weight, Sigma-Aldrich). 
Blood glucose levels were monitored by tail prick using a FreeStyle glucose monitoring system (Abbott 
Diabetes Care Inc.). In P10 pups, basal glycemia was measured at noon after approximately 2 hours of  
separation from mothers. Glucose tolerance tests were performed on animals fasted for 3 hours by i.p. 
injection of  a glucose solution (1.5 mg/g of  body weight), and glycemia was measured at 15 minutes, 
Downloaded from http://insight.jci.org on August 3, 2017.   https://doi.org/10.1172/jci.insight.93834
1 7insight.jci.org   https://doi.org/10.1172/jci.insight.93834
R E S E A R C H  A R T I C L E
30 minutes, 60 minutes, 90 minutes, and 120 minutes after glucose load. Serum insulin and glucagon 
levels were measured using an ultrasensitive mouse insulin ELISA kit (Alpco) and a mouse glucagon 
ELISA (RayBio).
Tissue dissection, collagenase digestion, and flow cytometry. Pancreatic tissue and spleens were dissected 
from P1 newborn pups or E14.5–E15.5 embryos obtained from time-dated pregnant females. Tissues 
were digested for 1 hour at 37°C in HBSS/0.1% collagenase A/20 μg/ml DNase I (Sigma-Aldrich). To 
facilitate dissociation of  the mesenchyme from the epithelial component of  the pancreas, the tissue was 
pipetted at 15-minute intervals during digestion. The resulting epithelial clusters were separated from the 
mesenchymal fraction through 3 rounds of  gravity sedimentations on sterile medium, followed by disso-
ciation of  the cell clusters into single cells using a nonenzymatic dissociation medium (Sigma-Aldrich). 
Purity of  cell fractions was assessed by immunostaining and flow cytometric analysis for the epithelial 
marker Ep-CAM, and the epithelial and mesenchymal components were defined as Ep-CAM positive 
and Ep-CAM negative, respectively. For flow cytometric analysis of  leukocyte subsets, pancreatic and 
splenic single-cell suspensions were blocked with mouse IgGs and anti-CD16/32 antibodies (clone 93) 
and immunostained with biotin anti-CD11b (clone M1/70), followed by Cy5.5-conjugated streptavidin, 
Alexa-488 anti-F480 (clone BM8), RPE-anti-GR1 (clone RBC-8C5), CY7/Percp anti-LY6G (clone 1A8), 
PE anti-CD115 (clone AFS98), RPE anti-CD206 (clone C068C2), FITC-anti-CD93 (clone AA41.1), 
RPE-anti-CD3e (clone 145-2C11), and biotin anti-B220 (clone RA3/6B2) (all from Biolegend) and RPE- 
or FITC-conjugated goat anti-CCR2 and anti-CX3CR1 antibodies (R&D Systems). The GR1 antibody 
recognizes an epitope shared by Ly6C and Ly6G antigens. While Ly6C is expressed on both monocytes 
and neutrophils, Ly6G is restricted mainly to neutrophils. In BrdU incorporation experiments, surface 
labeled cells were further processed for nuclear staining of  BrdU using a BrdU staining kit (Becton Dick-
inson), as per the manufacturer’s instructions. Cells were then analyzed with a FACSCalibur (Becton 
Dickinson). For purification of  islet epithelial cells, Ficoll-purified islets from P10 pancreas were dissoci-
ated into single cells by nonenzymatic dissociation; immunostained with anti-CD45 (clone 30F11, Bioleg-
end), anti-CD31 (clone 390, Biolegend), and EpCAM (clone G8.8, Biolegend) antibodies; and sorted as 
CD45negCD31negEpCAM+ cells using a FACSAria cell sorter.
CFU assays. For these experiments, pancreatic tissue from WT or CCR23RFP/WT mice at different ages 
(P1, P5, P15, and 4 weeks old) was microdissected, paying attention to exclude peripancreatic lymphatic 
structures and mesenteric tissue. Pancreas and spleen were digested into single cells using the collagenase 
method describe above. 1 × 105 cells were plated in duplicates in 1 ml of  complete Methocult medium 
(Stemcell Technologies) supplemented with recombinant SCF, IL-3, IL-6, and EPO (Stemcell Technol-
ogies) and cultured in a humidified 5% CO2 incubator for 7 to 10 days. BFU-Es were counted at day 3, 
whereas myeloid G-CFUs, M-CFUs, and GM-CFUs were scored between day 7 and day 10.
Organ cultures, pancreatic islets isolation, and islet-macrophage cocultures. Pancreata from P2 newborns 
were dissected, cut into 5–6 small fragments, and cultured for 5 days at the air-liquid interface of  0.4-
μm polycarbonate Transwells (Costar) in RPMI–5%FCS–1 × 10–5M β-mercaptoethanol in the presence 
or absence of  DT (50 ng/ml). Fifty percent of  the culture medium with or without DT was replaced 
daily. For islet isolation, pancreata from P10 mice were dissected and the tissue was inflated with a 
solution of  HBSS/Liberase (0.1 mg/ml)/Dnase I (20 μg/ml) under a dissecting microscope. The organs 
were then finely chopped and digested by shaking for 7 minutes at 2 g at 37˚C in a benchtop shaker. 
Islets were further purified by centrifugation over a Ficoll gradient (Histopaque 1077, Sigma-Aldrich) 
and hand picking. Islets insulin content was measured followed acid-ethanol extraction using an ultra-
sensitive insulin ELISA (Alpco). For measurement of  glucose-stimulated insulin secretion, islets were 
allowed to recover overnight in culture. The next day, 20–30 islets were hand picked in triplicates and 
cultured for 1 hour in Krebs buffer in the presence of  2.8 mM glucose, followed by 1 hour in the same 
buffer containing 16.7 mM glucose. Culture supernatants were recovered, and insulin was measured by 
ELISA. For islet-macrophage cocultures, islets purified from 5-week-old Ins-GFP–transgenic or WT 
mice were partially dissociated by trypsinization and plated on HTB9 (ATCC) matrix-coated coverslips. 
After overnight culture in RPMI–5%FCS, cells were serum starved in RPMI–0.1% FCS–0.1% BSA 
for 6 hours and then incubated in the same medium at 37°C in the presence or absence of  40 × 103 
FACS-sorted pancreatic CD11b+CCR2+ or CD11b+CCR2neg myeloid cells, with or without goat anti-
IGF2 blocking antibody (40 μg/ml, R&D Systems). After 24 hours, cells were fixed in 4% PFA and 
processed for histologic analysis.
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Histology and morphometric analysis. Pancreatic tissue was fixed in 4% PFA and embedded in OCT for his-
tology. Seven-micron cryostat sections were cut and processed for immunofluorescence. Briefly, after citrate 
antigen retrieval, sections were permeabilized in 0.05% Triton-X 100 and blocked in 50 mM glycine for 10 
minutes at room temperature, followed by incubation in 1% BSA/2% donkey serum for 1 hour at room tem-
perature. Primary antibodies used for immunostaining were as follows: mouse anti-E-cadherin (BD Biosci-
ences, clone 36/E-cadherin), goat anti-PDX-1 (gift of  M. Sander, UCSD, San Diego, California, USA), guin-
ea pig anti-insulin (A0564, Dako), mouse anti-glucagon (clone 79bB10, Sigma-Aldrich), mouse anti-PCNA 
(clone PC10, Santa Cruz Antibodies), rabbit anti-somatostatin (Dako), rabbit anti-PP (Invitrogen), rabbit 
anti-α-amylase (Sigma-Aldrich), rabbit anti-NCAM (gift of  K. Crossin, The Scripps Research Institute, La 
Jolla, California, USA), mouse anti-NKX6.1 (BCBC consortium), rabbit anti-MafA (IHC-00352, Bethyl), 
rabbit anti-Maf-B (IHC-00351, Bethyl), rabbit anti-RFP (600-401-379, Rockland), rabbit anti-GFP (A11122, 
Molecular Probes), rat anti-CD31 (clone Mec13.3, Biolegend), rabbit anti-Coll IV (ab6586, Abcam), and 
rabbit anti-IGF2 (ab9574 Abcam). Secondary antibodies (Jackson Immuno-Research Lab) were species-spe-
cific Fab2 fragments, Rhodamine Red–conjugated donkey anti-mouse IgG, FITC-conjugated donkey anti-
goat IgG, Cy5-conjugated donkey anti-guinea pig IgGs, Cy5, or FITC-conjugated donkey anti-rabbit IgGs. 
For in situ detection of  IGF2 and pospho-IGF1R, the TSA amplification kit (Molecular Probes) was used. 
Apoptotic cells were detected using the ApoTag-Fluorescein In Situ Apoptosis Detection Kit (Millipore) 
in combination with immunostaining for E-cadherin. After staining, sections were mounted and visual-
ized at a NIKON Eclipse-800 microscope equipped with a Spot II CCD camera or at a Zeiss Axiovert 
microscope equipped with a scanning laser confocal attachment (Nikon A1). Morphometric analysis was 
performed on tissue sections collected at approximately 100-μm intervals throughout the pancreas, using the 
Spot Advanced and ImageProPlus software. A total of  30–40 sections per antibody combination and per 
experimental group were screened. Periodic acid–Schiff  staining of  liver and muscle tissue was performed in 
accordance with the manufacturer’s instructions (Sigma-Aldrich, procedure 395).
RNA isolation and real-time PCR. RNA was isolated using the RNAeasy Kit (Qiagen), treated with DNase 
(Ambion) for 30 minutes at 37°C, and purified by phenol/chloroform extraction and ethanol precipitation. 
Purified RNA was retrotranscribed into cDNA using oligo dT primers and the Superscript III reverse tran-
scriptase (Invitrogen). Expression of specific genes was assayed by either standard semiquantitative PCR 
or in triplicates by real-time PCR using either the SensiMix SYBR green PCR master mix (Bioline) or the 
iTaq SYBR green amplification system (Bio-Rad). The following mouse-specific primer pairs were used: 18S 
forward GTAACCCGTTGAACCCCATT and reverse CCATCCAATCGGTAGTAGCG; E-cadherin for-
ward ACTGTGAAGGGACGGTCAAC and reverse TGTfCCCGGGTATCATCATCT; PDX-1 forward 
GAAATCCACCAAAGCTCACG and reverse TTCAACATCACTGCCAGCTC; Ngn3 forward GAGGCT-
CAGCTATCCACTGC and reverse TTGGAACTGAGCACTTCGTG; Neuro-D1 forward GCTCCAGGGGT-
TATGAGATCG and reverse CTCTGCATTCATGGCTTCAA; NKX6.1 forward GACGGAGAGTCAGGT-
CAAGG and reverse AGAGTTGGGTCCAGAGGTT; NKX2.2 forward TCTACGACAGCAGCGACAAC 
and reverse TTGTCATTGTCCGGTGACTC; PAX6 forward CAGCTTGGTGGTGTCTTTGT and reverse 
ACTTGGACGGGAACTGACAC; CD11b forward GCTTACCTGGGTTATGCTTCTGC and reverse 
GCTGCCCTTGATGCTAGTGT; CCR2 forward TCATCTGCAAAAACAAATCAAAGGA and reverse 
TAGTCATACGGTGTGGTGGC; CCL2 forward AAGCCAGCTCTCTCTTCCTC and reverse TCATTTG-
GTTCCGATCCAGG; CCL7 forward TTCCTCTTGGGGATCTTTTG and reverse TCTGTGCCTGCT-
GCTCATAG; CCL8 forward GAAGGGGGATCTTCAGCTTT and reverse TCTTTGCCTGCTGCT-
CATAG; IGF2 forward TGAGAAGCACCAACATCGAC and reverse ACTTCAGCAGCTCCCACTTC; 
IGFBP5 forward GGAAGACCTTGGGGGAGTAG and reverse TCAACGAAAAGAGCTACGGC; and 
IGFBP7 forward CTCAAGAACACCTTGGCACC and reverse CATCACCCAGGTCAGCAAG.
Real-time amplification conditions for mouse primers were 95°C for 15 seconds and 60°C for 45 sec-
onds for 40 cycles. For each primer combination, amplification efficiency was consistently >95%. Thresh-
old cycle numbers (Ct) were determined using the SDS 2.3 software (Applied Biosystems) and analyzed 
using the ΔΔCt method. All real-time PCR reactions were performed using either the 7900HT Real-time 
PCR system (Applied Biosystems) or the CFX96 real-time PCR system (Bio-Rad).
Immunoprecipitation and Western Blotting. Cell extracts were prepared using the NE-PER Cell Extraction 
Kit (Pierce) in the presence of  a cocktail of  protease inhibitors (Complete, Roche), phosphorylase inhib-
itors, and PMSF (1 mM). Protein concentration of  lysates was determined by the BCA protein assay 
(Pierce). For immunoprecipitation experiments, total proteins (300 μg) were incubated overnight at 4°C in 
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the presence of  rabbit anti-IGF1Rβ mAb (clone D23H3, Cell Signaling) or control rabbit IgGs, followed by 
absorption to Protein G-agarose beads. Immunocomplexes and total protein (5–10 μg) were then separat-
ed under reducing conditions onto 4%–12% polyacrilamide gels (Nu-Page, Invitrogen) and transferred by 
Western blotting onto PVDF membranes (Immobilon, Millipore). After blocking of  the membranes in 5% 
BSA or 1% dry milk−0.1% Tween-20 overnight at 4°C, the membranes were probed with rabbit anti-phos-
pho-IGF1Rβ (Tyr1135) (DA7A8, Cell Signaling), rat anti-Hsp90 (ab13494, Abcam), mouse anti-E-cadher-
in (clone 36/E-cadherin, BD Biosciences), mouse anti-Nkx6.1 (Ab2024, Beta Cell Biology Consortium), 
rabbit anti-MafA (Bethyl), and rabbit anti-Glut2 (07-1402, Millipore), followed by HRP-conjugated Protein 
A or donkey anti-rat, anti-mouse, or anti-rabbit secondary antibodies. Membrane-bound antibodies were 
detected by chemoluminescence using an ECL-detection kit (Amersham).
Adoptive transfer experiments. BM was obtained by flushing the femurs and tibias of  8- to 12-week-old 
C57BL/6-Tg(CAG-EGFP)10sb/J or CCR2WT/RFP mice using ice-cold RPMI–10% FCS. Single cells were 
then immunostained with a cocktail of  biotin-conjugated anti-TER-119, anti-CD3, anti-B220, and anti-
CD11c (BD Biosciences) antibodies, followed by RPE-conjugated streptavidin and anti-RPE magnetic 
beads (Miltenyi Biotec). Cells were then selected by negative selection on magnetic columns. Purity was 
validated by flow cytometric analysis for RPE+ contaminants and CY5-PE-labeled CD11b and GR1. 
This analysis routinely revealed that the negative fraction accounted for >99% CD11b+GR1+ myeloid 
cells. In experiments using BM from CCR2WT/RFP mice, GR1+CCR2+ cells were further sorted based 
on expression of  the RFP reporter using a FACsAria. Purified GR1+ (1 × 106 to 3 × 106/mouse) or 
GR1+CCR2RFP+ (0.2 × 106 to 0.3 × 106/mouse) cells were then injected intrahepatically into DT-treated 
or untreated newborn mice at P1 and P3; a third cell injection was performed i.p. at P5.
Illumina bead array. Pancreas and spleen were microdissected from WT E14.5 embryos (pools of  ~60) 
and P0 newborn pups (pools of  ~30) and digested by collagenase and CD11b+CCR2+ subsets were isolated 
by FACS sorting. mRNA from purified cells was prepared using the RNAeasy Kit (Qiagen) and run on 
a MouseWG-6 v2.0 Expression BeadChip as described previously (67). For each tissue sample, two bio-
logical replicates were interrogated using this array. Expression level data from the Illumina Bead Studio 
software were normalized using a quantile-loess algorithm (68). Probes whose expression level exceeded a 
threshold value in at least one sample were called detected. The threshold value was found by inspection 
from the distribution plots of  log expression levels. Two software programs were used to analyze the data 
sets, PARTEK and Ingenuity Pathway Analysis. Data from the Illumina microarray files were uploaded to 
the Partek Genomics Suite for differential expression and significance analysis. All array data were tested 
for sample quality using Partek quality metrics suite histograms, and PCA plots were generated to iden-
tify sample clustering and outliers within each sample group. Differential gene expression was performed 
within Partek using 1-way ANOVA with a P value of  less than 0.05. To ensure statistical quality, we plotted 
sources of  variation for each ANOVA performed based on the mean of  each sample in both control and 
treatment groups. Systems level analyses on differential expression genes were carried out using Ingenuity 
Pathway Analysis (Qiagen). Heatmaps were generated using mean values of  duplicate samples and the 
MeV_4_8 software developed by the TM4 Software Development Team (69). All array data have been 
deposited in the EBI ArrayExpress database (accession number E-MTAB-5427).
Statistics. Statistical significance of  differences in tissue morphometric analysis, flow cytometry, and 
real-time PCR experiments was validated by 2-tailed Student’s t test or by ANOVA 1-group variance test, 
followed by Bonferroni post-hoc test, using the Statview Software with limit for significance set at P < 0.05.
Study approval. All procedures were approved by the Institutional Animal Care and Use Committee of  
the University of  Washington.
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